title: The role of entacapone in the management of Parkinson's disease.
abstract: Catechol-O-methyltransferase (COMT) inhibition is an important advance in the treatment of Parkinson's disease. This consensus statement provides guidelines for the optimal use of the only currently available COMT inhibitor, entacapone (Comtess, Orion Pharma (UK) Ltd, Newbury, Berkshire).
authors.affiliation: Imperial College School of Medicine, Hammersmith Hospital, London.
authors.forename: D J
authors.initials: DJ
authors.lastname: Brooks
authors.forename: D
authors.initials: D
authors.lastname: Forsyth
authors.forename: J R
authors.initials: JR
authors.lastname: Playfer
authors.forename: A C
authors.initials: AC
authors.lastname: Williams
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D008297:Male; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos
chemical_list: D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D004791:Enzyme Inhibitors; D009570:Nitriles; D010919:Placebos; D007980:Levodopa; C071192:entacapone